Online inquiry

IVTScrip™ mRNA-Anti-MSTN, REGN-1033(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ13766MR)

This product GTTS-WQ13766MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets MSTN gene. The antibody can be applied in Sarcopenia research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_005259.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2660
UniProt ID O14793
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MSTN, REGN-1033(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ13766MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11081MR IVTScrip™ mRNA-Anti-CSF1, MCS-110(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MCS-110
GTTS-WQ7080MR IVTScrip™ mRNA-Anti-FAP, FAP-IL2v(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA FAP-IL2v
GTTS-WQ14320MR IVTScrip™ mRNA-Anti-EGFL7, RG7414(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA RG7414
GTTS-WQ11804MR IVTScrip™ mRNA-Anti-PDCD1, MK-3475(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MK-3475
GTTS-WQ3575MR IVTScrip™ mRNA-Anti-LYPD3, BAY 1112623(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA BAY 1112623
GTTS-WQ1414MR IVTScrip™ mRNA-Anti-MUC16, ACA125(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ACA125
GTTS-WQ11349MR IVTScrip™ mRNA-Anti-CD19, MEDI-551(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MEDI-551
GTTS-WQ14996MR IVTScrip™ mRNA-Anti-CD19, SJ25C1 scFv-28Z CAR(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA SJ25C1 scFv-28Z CAR
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW